Cathie Wood has seldom shied away from letting everyone know where she believes the next wave of market-changing businesses will come from. Though ARK Invest’s daily trades spark a ton of excitement, its latest buying in CRISPR Therapeutics (CRSP) is far from being a sudden shift. The speculative healthcare stock specializes in gene editing, a technology that’s a key component of Wood’s vision for transformational innovation. Think of gene editing the way investors thought of the internet back in the 90 ...